Plozasiran (ARO-APOC3) Decreases APOC3 and Triglycerides (TG) in Patients With Mixed Hyperlipidemia: MUIR Final Results
Plozasiran (ARO-APOC3) Decreases APOC3 and Triglycerides (TG) in Patients With Mixed Hyperlipidemia: MUIR Final Results
Revolutionizing Care for Patients With T2D and Obesity: From Pathophysiology to Personalized Treatments
Revolutionizing Care for Patients With T2D and Obesity: From Pathophysiology to Personalized Treatments
A Practical Look at Cardiorenal Protection for CKD in T2D: Applying Recent Data
A Practical Look at Cardiorenal Protection for CKD in T2D: Applying Recent Data
Main Messages of New ESC Guidelines for CVD Management in Diabetes
Main Messages of New ESC Guidelines for CVD Management in Diabetes
Addressing Patient Management in ASCVD Risk Reduction: A Collaborative Approach
Addressing Patient Management in ASCVD Risk Reduction: A Collaborative Approach